Get started
Author

Francesca Norelli

ORCID: 0009-0000-5260-236X
Observed ORCID: 0009-0000-5260-236X
OpenAlex ID: A5093697589
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence
2024 · Marco Caminati, Claudio Micheletto, et al. · Expert Opinion on Biological Therapy · 21
Adherence to Intranasal Steroids in Chronic Rhinosinusitis with Nasal Polyposis Prior to and during Biologic Therapy: A Neglected Matter
2024 · Francesca Norelli, Michele Schiappoli, et al. · Journal of Clinical Medicine · 19
PDF
Melittin in A llergo O ncology: From Honey Bee Venom to Anti‐Cancer Therapeutic Innovation—An EAACI Position Paper
2026 · Teodorikez‐Wilfox Jimenez‐Rodriguez, Luljeta Ahmetaj, et al. · Allergy · 2
Safety and efficacy of extended venom immunotherapy maintenance intervals in mastocytosis
2025 · Giovanna Sfriso, Matteo Martini, et al. · The Journal of Allergy and Clinical Immunology In Practice · 2
Hymenoptera venom allergy in children and adolescents
2024 · Francesca Norelli, Valentina Gueli, et al. · Current Opinion in Allergy and Clinical Immunology · 2
Venom immunotherapy in children and adolescents: Efficacy and safety in an Italian tertiary allergy center
2026 · Valentina Gueli, Francesca Norelli, et al. · Pediatric Allergy and Immunology
PDF
Author response for "Venom immunotherapy in children and adolescents: efficacy and safety in an Italian tertiary allergy center"
2026 · Valentina Gueli, Francesca Norelli, et al. · Publons reviews and discussion
Safety of Drug Provocation Tests in Adults With and Without Clonal Mast Cell Disorders
2025 · Francesca Nalin, Bianca Olivieri, et al. · Allergy
Works count: 8
Citation count: 46
H-index: 2
I10-index: 2
Year
Topic
Type